MaxCyte increases dose level for mesothelioma and ovarian cancer patients in its Phase I trials.
MaxCyte Inc (LON: MXCT) CEO Doug Doerfler sat down with Proactive at the BIO Investor Forum in San Francisco.
Doerfler says the company is making 'exciting progress' with its early-stage cancer drug developed using its CARMA technology.
The objective of a study of this kind is to assess whether the drug is safe and well-tolerated.
To access, purchase, authenticate, or subscribe to the full-text of this article, please visit this link: https://www.proactiveinvestors.com/companies/news/905581/maxcyte-increases-dose-level-for-mesothelioma-and-ovarian-cancer-patients-in-its-phase-i-trials-905581.html
|Printer friendly Cite/link Email Feedback|
|Publication:||Proactive Investors United States|
|Date:||Oct 25, 2019|
|Previous Article:||NetCents Technology reports consistent growth in new merchant cryptocurrency signups.|
|Next Article:||Nutritional High sign exclusive agreement with Golden Triangle Brands to U.S.|